Two of our hit compounds, #5333 (also called SVI-5333) and #5338 (also called SVI-5338), had a significantly increased therapeutic window compared to WS6 and inhibited the malignant phenotype of neuroblastoma cells in vitro, which partly depended on PA2G4 and MYCN expression. This evidence concerns the gene PA2G4 and neuroblastoma.